港股创新药精选ETF(520690)今日正式上市交易，其标的指数年内涨幅101.58%

Group 1 - The Hong Kong Stock Exchange's innovative drug-focused ETF (520690) has officially launched, closely tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on leading innovative drug companies and high liquidity, research-intensive stocks [1] - Key weighted stocks in the index include BeiGene, Innovent Biologics, WuXi Biologics, CanSino Biologics, CSPC Pharmaceutical Group, China National Pharmaceutical Group, 3SBio, Hansoh Pharmaceutical, Zai Lab, and WuXi AppTec [1] - As of July 31, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has seen a year-to-date increase of 101.58% [1] Group 2 - Industry experts believe that China's innovative drug industry is undergoing a strategic leap from quantitative to qualitative changes, driven by demographic shifts, policy benefits, and technological breakthroughs [1] - The Chinese pharmaceutical innovation ecosystem is transitioning from "following innovation" to "leading innovation," marking a historic transformation [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index serves as the first precise index tool focused on this sector, providing investors with an efficient means to participate in this transformation through rigorous compilation rules and dynamic optimization mechanisms [1] Group 3 - With ongoing policy benefits, emerging corporate profit inflection points, and strengthening global competitiveness, the index is expected to become a core allocation target for sharing the dividends of China's pharmaceutical innovation [1]